Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://t.co/ygEDQwwrad #thestockmonkey #stockmarket #stocks #trading  #daytrading #stockmarket  #darkpool #blocktrades